Long-acting nifedipine versus metoprolol as monotherapy for essential hypertension. A randomized, controlled crossover study.
We assessed the efficacy of long-acting nifedipine as monotherapy in 52 patients with mild to moderate essential hypertension in a randomized, controlled crossover study. Good blood pressure control was achieved in 34 of 40 patients (85%) receiving nifedipine (mean daily dose, 52 mg in 2 divided doses) compared with 23 of 40 patients (58%) receiving metoprolol (mean daily dose, 155 mg in 2 divided doses). After treatment for 4 weeks, the mean blood pressures with nifedipine (149.7 +/- 16.6/88.7 +/- 11.1 mm of mercury) and metoprolol administration (163.9 +/- 23.3/94.2 +/- 10.2 mm of mercury) were significantly lower than with placebo (176.7 +/- 17.3/100.9 +/- 7.1 mm of mercury) (P less than .05). The mean systolic pressure during nifedipine treatment was 14.2 mm of mercury lower (95% confidence interval [CI], 3.9 to 24.5 mm of mercury) and mean diastolic pressure 5.5 mm of mercury (95% CI, 0.3 to 10.7 mm of mercury) lower than with metoprolol therapy. Both drugs were reasonably well tolerated, and intolerance requiring withdrawal was encountered in 3 of 45 (7%) patients receiving nifedipine, compared with 1 of 45 (2%) of those taking metoprolol and placebo, respectively. Adverse effects of nifedipine, most of which were transient, included palpitations, headache, facial flushing, and ankle edema. Long-acting nifedipine is a promising agent when given alone for mild to moderate hypertension and can be safely administered in clinical practice.
Department of Medicine, Chinese University of Hong Kong.
K S
KS
Woo
C O
CO
Pun
D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008790:Metoprolol / Q000627:therapeutic use*; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D003692:Delayed-Action Preparations; D008790:Metoprolol; D009543:Nifedipine